PFE  Pfizer Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

191.3B

Vuru Grade

73.11/100

Current Price

$29.99
-0.20 (-0.66%)

Growth Price

$30.26
Fairly valued

Stability Price

$11.53
Overvalued by 61.56%

Company Metrics

  • 9.37 P/E
  • 3.81 P/S
  • 2.48 P/B
  • 3.222 EPS
  • 11.61% Cash ROIC
  • 1.39 Cash Ratio
  • 1 / 3.31% Dividend
  • 27.17M Avg. Vol.
  • 6.38B Shares
  • 191.3B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Pfizer Earnings May Miss As Revenues Fall Due To Patent Expiry
Bidness Etc - 8 hours ago
Pfizer is also looking forward to acquiring Innopharma, a company with 19 products in its pipeline for $360 million.
Why Pfizer (PFE) Stock Is Lower Today
TheStreet.com - 8 hours ago
"We rate PFIZER INC (PFE) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover.
Pfizer Inc. (PFE) Q2 Earnings Preview: A Penny Here a Penny There - iStockAnalyst (press release)
Pfizer Inc. (NYSE:PFE) slipped -0.49% - Street Register
Pfizer's need for deal looms larger with earnings report
Chicago Tribune - 17 hours ago
NEW YORK (Reuters) - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals ...
Why Pfizer Will Trade At $40 On Improved Drug Pipeline (PFE)
Seeking Alpha (registration) - 7 hours ago
The main talking points these days surrounding Pfizer (NYSE:PFE) continues to surround the company's perceived eroding drug pipeline.
PREVIEW-Pfizer's need for deal looms larger with earnings report
CNBC.com - 17 hours ago
NEW YORK, July 28 (Reuters) - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or ...
Pfizer Needs to Do a Deal, Analyst Says
Wall Street Journal (blog) - Jul 24, 2014
Still, Mr. Boris predicts that without an acquisition by the end of 2015, only 38% of Pfizer's revenue will come from the U.S.
Pfizer Needs to Do a Deal, Analyst Says - PFE - Street Register
Is Pfizer Inc. (PFE) Poised to Beat Earnings Estimates?
Zacks.com - 1 hour ago
Pfizer Inc. (PFE - Analyst Report) is scheduled to report second quarter 2014 results before the opening bell on Jul 29. Why a Likely Positive Surprise?
Interesting November Stock Options for Pfizer
Forbes - 6 hours ago
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Pfizer Inc (NYSE: PFE). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Pfizer to Acquire InnoPharma, Inc.
MarketWatch - Jul 16, 2014
NEW YORK and PISCATAWAY, N.J., Jul 16, 2014 (BUSINESS WIRE) -- Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will ...
Pfizer Inc. (NYSE:PFE) Announced Acquisition Of InnoPharma For An Upfront ... - USTrade Voice
Whisper Number Impact: How Will Pfizer's Stock Move After Earnings? (PFE)
Seeking Alpha (registration) - 4 hours ago
Pfizer Inc. (NYSE:PFE) is expected to report earnings on Tuesday, July 29th. The whisper number is $0.59, two cents ahead of the analysts' estimate and showing some confidence from investors.